Novasoy Soy Isoflavone Powder

Evidence that soyasaponin Bb retards disease progression in a murine model of polycystic kidney disease.
Kidney Int. 2003 April. Philbrick DJ, Bureau DP, Collins FW, Holub BJ. Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.
We reported a lessened cyst growth in the pcy mouse model of polycystic kidney disease (PKD) when mice were fed a soy protein isolate-based diet and hypothesized that the soyasaponins may be associated with this therapeutic effect. The effects of feeding a saponin-enriched alcohol extract  from soy protein isolate, an isoflavone- and saponin-enriched soy supplement (Novasoy 400), or a 99.5% pure soyasaponin Bb powder on cyst growth are reported here. The therapeutic effects of the Novasoy Soy Isoflavone Powder were studied in 60-day-old male pcy mice in two separate, 90-day feeding trials. In the first study, mice were fed either a casein-based (control) diet, a diet in which SPI replaced the casein or the control diet supplemented with Novasoy Soy Isoflavone Powder. In the second study, mice were fed the control diet unsupplemented or supplemented with either a soyasaponin- and isoflavone-enriched soy product (Novasoy 400) or a 99.5% pure soyasaponin Bb powder.  In study 1, kidney weight, water content, and plasma creatinine and urea levels were markedly reduced in the Novasoy Soy Isoflavone Powder -fed animals compared to tissues from the control group; likewise, mice fed the SPI-based diet showed a decreased plasma creatinine, but only a slightly reduced plasma urea. In study 2, kidney weight, water content, plasma creatinine and urea levels were significantly reduced in mice fed the soyasaponin Bb powder and the Novasoy-400 supplement, compared to controls. Soyasaponin Bb can impede kidney enlargement and cyst growth in the pcy mouse model of PKD. Further studies are needed to determine its most effective dose and mechanism of action.

Multivitamins information